Literature DB >> 3061637

Central mechanisms and levodopa response fluctuations in Parkinson's disease.

M M Mouradian1, T N Chase.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3061637     DOI： 10.1097/00002826-198808000-00007

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  6 in total

1.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Sustained-release of levodopa: single dose study of a new formulation.

Authors:  M Gerlach; W Kuhn; T Müller; P Klotz; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

5.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.

Authors:  M Rodriguez; G Lera; J Vaamonde; M R Luquin; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

6.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

Authors:  M W Horstink; J C Zijlmans; J W Pasman; H J Berger; M A van't Hof
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-03       Impact factor: 10.154
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.